Literature DB >> 7762496

High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography.

J J Mahmarian1, L A Moyé, M S Verani, M F Bloom, C M Pratt.   

Abstract

The purpose of this study was to define the reproducibility of sequential quantitative exercise thallium-201 tomography. This was an ancillary study of a randomized, double-blind, placebo-controlled trial evaluating the short-term efficacy of transdermal nitroglycerin patches in stable patients with angiographic coronary artery disease and no prior myocardial infarction. All 18 patients had a baseline tomographic perfusion defect involving > or = 5% of the left ventricle after treadmill exercise. At a minimum of 3 days (mean 6.1 +/- 1.8) after double-blind randomization to placebo, exercise thallium-201 tomography was repeated (study 2) using the same exercise protocol as in the baseline study (study 1). No significant differences in exercise parameters were observed from studies 1 to 2. Seventeen of 18 patients (94%) had an abnormal repeat exercise perfusion scan and 96% of initially abnormal vascular territories remained abnormal. The mean tomographic perfusion defect size was not significantly different from studies 1 (17.4 +/- 13.3%) to 2 (16.6 +/- 15.3%), nor were the components defined as scar and ischemia. A > or = 10% change in total perfusion defect size in an individual patient defined the 95% confidence interval for exceeding the variability of the tomographic technique. Quantitative exercise thallium-201 tomography is highly reproducible and can be used to accurately interpret temporal changes in myocardial perfusion in individual patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762496     DOI: 10.1016/s0002-9149(99)80741-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  24 in total

1.  Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts.

Authors: 
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

2.  Follow-up testing: the beginning of an answer.

Authors:  R J Gibbons
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

3.  Monitoring medical management of coronary artery disease: patient selection, optimal management, and potential problems for diagnosis.

Authors:  M D Cerqueira
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

4.  Lake Tahoe invitation meeting 2002.

Authors: 
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

Review 5.  Advances in quantitative perfusion SPECT imaging.

Authors:  Edward P Ficaro; James R Corbett
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

Review 6.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 7.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

8.  Patient-centered imaging.

Authors:  E Gordon Depuey; John J Mahmarian; Todd D Miller; Andrew J Einstein; Christopher L Hansen; Thomas A Holly; Edward J Miller; Donna M Polk; L Samuel Wann
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

9.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

10.  Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial: A randomized, prospective multicenter trial evaluating the role of adenosine Tc-99m sestamibi SPECT for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction.

Authors:  John J Mahmarian; Leslee J Shaw; Gerald H Olszewski; Bradley K Pounds; Maria E Frias; Craig M Pratt
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.